Scarica l'app Stockscreener
10.64
3.10%
-0.34
Dopo l'orario di chiusura:
10.53
-0.11
-1.03%
Precedente Chiudi:
$10.98
Aprire:
$10.99
Volume 24 ore:
120.48K
Relative Volume:
0.67
Capitalizzazione di mercato:
$351.99M
Reddito:
$65.42M
Utile/perdita netta:
$-32.96M
Rapporto P/E:
-8.378
EPS:
-1.27
Flusso di cassa netto:
$-19.87M
1 W Prestazione:
-1.39%
1M Prestazione:
+8.57%
6M Prestazione:
+2.01%
1 anno Prestazione:
+65.22%
Intervallo 1D:
$10.60
$11.19
Intervallo di 1 settimana:
$10.15
$11.25
Portata 52W:
$5.45
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Nome
Neuropace Inc
Settore
Industria
Telefono
(650) 237-2700
Indirizzo
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Confronta NPCE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
10.64 | 357.94M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
127.63 | 231.95B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
97.78 | 142.60B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
369.25 | 141.45B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.04 | 123.83B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.65 | 43.07B | 5.69B | 1.41B | 577.90M | 6.9828 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-21 | Iniziato | UBS | Buy |
| 2024-03-14 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Iniziato | Leerink Partners | Outperform |
| 2023-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Iniziato | Lake Street | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Iniziato | Robert W. Baird | Outperform |
| 2021-05-17 | Iniziato | JP Morgan | Overweight |
| 2021-05-17 | Iniziato | Morgan Stanley | Overweight |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Neuropace Inc Borsa (NPCE) Ultime notizie
Can NeuroPace Inc. rally from current levelsMarket Growth Summary & High Conviction Buy Zone Alerts - newser.com
Will NeuroPace Inc. price bounce be sustainableJuly 2025 Gainers & Consistent Growth Equity Picks - newser.com
How to integrate NeuroPace Inc. into portfolio analysis tools2025 Retail Activity & Long-Term Safe Investment Plans - newser.com
Can NeuroPace Inc. stock withstand economic slowdown2025 Retail Activity & Reliable Trade Execution Plans - newser.com
NeuroPace Inc. stock outlook for YEAR2025 Breakouts & Breakdowns & Weekly High Potential Stock Alerts - newser.com
Will NeuroPace Inc. stock gain from government policiesJuly 2025 PreEarnings & Stepwise Trade Execution Plans - newser.com
Tools to assess NeuroPace Inc.’s risk profileGold Moves & Daily Entry Point Alerts - newser.com
Applying Elliott Wave Theory to NeuroPace Inc.July 2025 Breakouts & Real-Time Market Trend Scan - newser.com
Can NeuroPace Inc. stock sustain revenue growthTreasury Yields & Community Verified Trade Alerts - newser.com
NeuroPace, Inc. (NASDAQ:NPCE) Receives $16.60 Average Price Target from Analysts - Defense World
NeuroPace's (NPCE) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Automated trading signals detected on NeuroPace Inc.Trade Analysis Summary & Free Technical Pattern Based Buy Signals - newser.com
What momentum shifts mean for NeuroPace Inc.2025 Market Overview & Community Consensus Stock Picks - newser.com
NeuroPace Inc. recovery potential after sell offInsider Selling & Verified Swing Trading Watchlist - newser.com
What analysts say about NeuroPace Inc stockEx-Dividend Date Alerts & Stay One Step Ahead of Risk Events - earlytimes.in
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
NeuroPace Inc Stock Analysis and ForecastDouble Top/Bottom Patterns & Affordable Portfolio Growth - earlytimes.in
Using economic indicators to assess NeuroPace Inc. potentialJuly 2025 Setups & AI Powered Market Entry Ideas - newser.com
HighMark Wealth Management LLC Purchases 60,000 Shares of NeuroPace, Inc. $NPCE - MarketBeat
Neuropace chief medical officer Morrell sells $48,032 in stock - MSN
What drives NeuroPace Inc stock priceTrading Volume Surges & Get Mentorship from Elite Traders - earlytimes.in
Epilepsy Treatment Devices Market Hits New High | Medtronic, NeuroPace, LivaNova, Boston Scientific - newstrail.com
Why NeuroPace Inc. stock is trending among retail tradersJuly 2025 Final Week & Growth Focused Stock Pick Reports - The British Mountaineering Council
Palumbo Wealth Management LLC Grows Stake in NeuroPace, Inc. $NPCE - MarketBeat
Why NeuroPace Inc. is moving todayGap Down & Comprehensive Market Scan Reports - newser.com
Will NeuroPace Inc. outperform the marketWeekly Profit Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Is NeuroPace Inc. building a consolidation baseInsider Selling & Short-Term Swing Trade Alerts - newser.com
Neuropace Inc Azioni (NPCE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neuropace Inc Azioni (NPCE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Morrell Martha | CHIEF MEDICAL OFFICER |
Feb 21 '25 |
Sale |
13.72 |
78,334 |
1,074,844 |
81,993 |
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
1.23%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):